Contract Pharma | Pharma Matters Q&A interview with our CEO, Jarlath Keating

In recent years, lipid nanoparticles (LNPs) have emerged as a groundbreaking technology in the pharmaceutical world, revolutionizing the delivery of complex therapeutic molecules like RNA and DNA. Their ability to encapsulate and protect sensitive payloads has proven pivotal in overcoming long-standing challenges in drug delivery, from poor cellular uptake to enzymatic degradation. Notably, the success of mRNA-based COVID-19 vaccines has propelled LNPs into the global spotlight, underscoring their potential in advancing precision medicine and transforming healthcare.

In this exclusive Q&A, Jarlath Keating, CEO of Phosphorex, talks about the critical role of LNPs in drug formulation and development. From addressing their unique advantages and challenges to highlighting Phosphorex’s expertise and vision for the future, Keating sheds light on how his team is pioneering innovations in non-viral drug delivery systems.

Click here for the full Q&A:
https://www.contractpharma.com/library/revolutionizing-drug-delivery-insights-into-lipid-nanoparticles/